Home > Insider Trading > Filing (0001140361-10-004715)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1263078	C William Wallen	One Idexx Drive Westbrook ME 04092	Senior Vp & Cso	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-02-04	10,000	$21.30	28,668	No	4	M	Direct
Common Stock	Disposition	2010-02-04	10,000	$50.32	18,668	No	4	S	Direct
Common Stock	Acquisiton	2010-02-08	13,530	$21.30	32,198	No	4	M	Direct
Common Stock	Disposition	2010-02-08	13,530	$50.00	18,668	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Options (right to buy)	Disposition	2010-02-04	10,000	$0.00	10,000	$21.30
Common Stock	Non-Qualified Stock Options (right to buy)	Disposition	2010-02-08	13,530	$0.00	13,530	$21.30

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,530		2013-09-08	No	4	M	Direct
0		2013-09-08	No	4	M	Direct

Footnotes

The sale price reported above reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged between $50.20 and $50.41. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
Includes 54 shares of common stock acquired pursuant to the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2009.
Grant of options to buy shares of common stock becomes exercisable in five equal annual increments, beginning on the first anniversary date (9/8/2004) of the date of grant.